SCHEMBL6031765

SCHEMBL6031765

Nc1nc2c(c3c1ncn3O)CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 9/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
BPTF Q12830 1/20 0.38
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
KDM4E B2RXH2 8/20 0.36
HSD17B10 Q99714 6/20 0.36
ALDH1A1 P00352 6/20 0.36
HPGD P15428 4/20 0.36
CHRNE Q04844 2/20 0.35
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
BCHE P06276 4/20 0.33
GRIN1 Q05586 4/20 0.33
GRIN2A Q12879 4/20 0.33
CACNB4 O00305 1/20 0.33
CACNA1A O00555 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13921708 0.81 CDK1 (0.41) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL8126995 0.76 ADORA2A (0.46) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL8124044 0.76 HSD17B10 (0.44) ACHEMAPK1KDM4EHSD17B10ALDH1A1
SCHEMBL7006782 0.76 TLR7 (0.55) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL5139514 0.76 NOS3 (0.33) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL3176199 0.76 TK1 (0.43) ACHEALDH1A1CHRNE
SCHEMBL5139518 0.76 AHCY (0.35) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL8114300 0.75 CSNK2A2 (0.43) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL2059204 0.75 TLR7 (0.53) ACHEMEN1KMT2ANOS3NOS1
SCHEMBL8113946 0.74 TLR7 (0.54) ACHEMEN1KMT2AMAPK1BPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115622-B2 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-03 US disclosed
US-6989389-B2 Aryl ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2006-01-24 US disclosed
US-6953804-B2 Aryl ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2005-10-11 US disclosed
US-20050143413-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2005-06-30 US disclosed
US-20040157874-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-08-12 US disclosed
US-20040138248-A1 Aryl ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-15 US disclosed
US-20040106640-A1 Aryl ether substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. 2004-06-03 US disclosed
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US disclosed
US-20040067975-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-08 US disclosed
US-6677348-B2 INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US disclosed
US-6660747-B2 Contain ether and amide functionality at the 1-position; useful as immune response modifiers and can induce biosynthesis of various cytokines; useful in treatment of viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-12-09 US disclosed
US-20030212092-A1 Aryl ether substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. 2003-11-13 US disclosed
US-20030212091-A1 Aryl ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-11-13 US disclosed
US-20030187016-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US disclosed
EP-1341789-A2 ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-10 EP disclosed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP disclosed
US-20030096835-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed
WO-2002046189-A2 ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187016-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ACHE 4517/4885MEN1 1873/4885KMT2A 744/4885
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 ACHE 4670/4885MEN1 2581/4885KMT2A 808/4885
US-20050143413-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ACHE 4517/4885MEN1 1873/4885KMT2A 744/4885
US-20040157874-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ACHE 4517/4885MEN1 1873/4885KMT2A 744/4885
US-20040138248-A1 Aryl ether substituted imidazoquinolines IRF3, IFNG, MYD88 ACHE 4824/4885MEN1 3931/4885KMT2A 663/4885
US-20040067975-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ACHE 4517/4885MEN1 1873/4885KMT2A 744/4885
US-20040106640-A1 Aryl ether substituted imidazoquinolines IRF3, IFNG, MYD88 ACHE 4824/4885MEN1 3931/4885KMT2A 663/4885
US-20030212092-A1 Aryl ether substituted imidazoquinolines IRF3, IFNG, MYD88 ACHE 4824/4885MEN1 3931/4885KMT2A 663/4885
US-20030096835-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ACHE 4517/4885MEN1 1873/4885KMT2A 744/4885
US-20030212091-A1 Aryl ether substituted imidazoquinolines IRF3, IFNG, MYD88 ACHE 4824/4885MEN1 3931/4885KMT2A 663/4885
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 ACHE 4670/4885MEN1 2581/4885KMT2A 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.